Chronic human immunodeficiency virus-1 (HIV-1) infection in patients leads to multilineage hematopoietic abnormalities or pancytopenia. The deficiency in hematopoietic progenitor cells (HPCs) induced by HIV-1 infection has been proposed, but the relevant mechanisms are poorly understood. We report here that both human CD34 
Author summary
Multi-lineage hematopoietic abnormalities generally occur during chronic infection which results in a disorder of human leukocyte development and differentiation, contributing to human immunodeficiency virus-1 (HIV-1)-infection induced immune-pathogenesis in AIDS patients. Although successful antiretroviral therapy can reduce plasma viral loads to undetectable levels and ameliorate HIV-1-associated hemato-suppression, immune cell development is only partially restored. The mechanism for the abnormal hematopoiesis occurring during chronic HIV-1 infection remains unclear. HIV-1 infection may directly or indirectly functionally impair hematopoietic progenitors by either viral products or induction of persistent inflammatory responses, leading to hematopoiesis 
Introduction
Human immunodeficiency virus-1 (HIV-1) infection in patients leads to multi-lineage hematopoietic abnormalities, including anemia, granulocytopenia and thrombocytopenia [1, 2] . Abnormalities in fetal hematopoiesis have also been reported in aborted fetuses from HIV-1 seropositive women [3] . The defect in hematopoietic progenitor cells (HPCs) or hematopoiesis induced by HIV-1 has been proposed [1, 4, 5] . In addition, the degree of the hematopoietic pathology correlates with the stage of disease progression [6] , and end-stage disease is characterized by pancytopenia [1] . Long-term bone marrow (BM) cultures from HIV-1-infected patients exhibit low CD34 + progenitor cell growth and differentiation [7, 8] , indicating functional impairment of early hematopoietic progenitors. Although the successful highly active antiretroviral therapy (HAART) clearly ameliorates HIV-1-associated hemato-suppression, it does not completely restore blood cell development [9] . These observations indicate that hematopoietic failure is an important aspect of HIV-1 infection-induced pathogenesis [10] . HPCs are comprised of diverse populations, including both early and intermediate progenitors. Each subpopulation expresses distinct sets of cell surface antigens, although they all express the cell surface antigen CD34 [11, 12] . Early and intermediate populations can be distinguished by the expression of CD38, with the former being negative for CD38 and the latter being positive for this antigen. Functionally, intermediate progenitors include common myeloid progenitors that can give rise to all myeloid, erythroid and megakaryocyte lineages. Due to limited access to the BM in humans, properties of human HPC subsets and their alterations in healthy and HIV-1 disease states have been difficult to characterize.
The mechanisms underlying abnormal hematopoiesis in HIV-1 infection remains unclear due to the paucity of robust animal models that mimic human hemato-suppression in vivo. Although previous studies failed to detect HIV-1 infection of HPCs, recent reports indicated that HIV-1 could directly infect HPC subsets and lead to their impairment [13] [14] [15] [16] . In addition, HIV-1 proteins such as Nef [17] and prolonged treatment with antiretroviral drugs could also compromise hematopoietic progenitors [18] . Although these studies investigated a litany of direct and indirect causes of HIV-1-associated hemato-suppression, how HIV-1 affects hematopoiesis in vivo remains unclear.
There is emerging evidence that certain cytokines induced during inflammation have significant effects on HPCs in the BM. Type I and II interferon (IFN) [19] [20] [21] [22] [23] , tumor necrosis factor (TNF) [24] [25] [26] and lipopolysaccharide (LPS) [27, 28] directly stimulate HPC proliferation and differentiation, thereby increasing the short-term output of mature effector leukocytes. However, chronic inflammatory cytokine signaling can lead to functional exhaustion of HPCs [19, 22, 28] . Our previous study demonstrated that plasmacytoid dendritic cells (pDCs), the major type I interferon (IFN-I)-producing cells during acute or chronic HIV-1 infection, could inhibit viral replication while significantly contributing to HIV-1 infection-induced immune-pathogenesis, including increased immune cell death and reduced immune reconstitution of human CD45 + cells in humanized mice in vivo [29] . These findings suggest that pDCs play a pivotal role in the hemato-suppression induced by chronic HIV-1 infection.
In this study, we sought to understand the role of pDCs in HIV-1-associated hemato-suppression in a humanized mouse model in vivo. We discovered that HIV-1 infection depleted CD34 +
CD38
-early HPCs and functionally impaired human CD34 + HPCs in the BM of patients and humanized mice with HIV-1 infection. This phenomenon was further found to be dependent on pDCs, as depletion of pDCs significantly recovered HPC cell numbers and multi-lineage colony-forming functions. Our present study therefore reveals a novel mechanism for hematopoiesis suppression induced by chronic HIV-1 infection and provides a new strategy to rescue HPC function and halt HIV-1 disease progression. Fig 1A) .
Results

Development and maintenance of functional human HPCs in humanized mice
To determine if human HPCs derived from humanized mice were functional, human CD34 + cells were isolated from the BM of humanized mice and human fetal livers, and colony-forming unit (CFU) assays were performed by culturing CD34 + HPCs in a complete methylcellulose medium system. Two weeks later, HPCs derived from the BM of humanized mice produced 50 colonies on average for every 500 CD34 + cells plated, similar to that of human fetal liver-derived CD34 + cells (Fig 1B) . All hematopoietic lineages were generated in cultures from the BM of humanized mice. In addition, HPCs from humanized mice could proliferate and differentiate into various blood lineage cells in vitro at a similar frequency to that of CD34 + cells from human fetal livers, including colony-forming unit-granulocyte and macrophage (CFU-GM), colony-forming unit-erythroid (CFU-E) and colony-forming unit-granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM) (Fig 1B) . We then measured the proliferation capacity of HPCs by BrdU labeling in vivo and found that 8.9% of human CD34 + cells showed proliferation (Fig 1C) . (Fig 2G) . In contrast, the proportion of intermediate CD34 +
CD38
+ HSCs was increased within total HPCs in HIV-1-infected patients relative to those of HC subjects ( Fig  2H) . These data indicated that early CD34 + CD38 -HSCs were preferentially depleted by chronic HIV-1 infection, and the humanized mouse is a highly relevant animal model that mimics HIV-1-induced hemato-suppression conditions in patients.
Chronic HIV-1 infection inhibits proliferation of human HPCs in vivo
We reduced by chronic HIV-1 infection (Fig 3B and 3C ). In terms of cell numbers, the early HPC counts were significantly decreased by chronic HIV-1 infection compared with mock treatment in mice (Fig 3D) , while intermediate HPC counts were only slightly reduced ( Fig 3E) . Thus, while both cell types were less proliferative in the presence of HIV-1, the more marked difference was observed in CD34 whereas HPCs derived from HIV-1-infected mice produced less than 30 colonies per 500 CD34 + HPCs. Moreover, the ability of HPCs to generate all lineages, including GM, E and GEMM, was also suppressed to some extent in chronically infected mice. Therefore, the results indicated that chronic HIV-1 infection leads to the impaired differentiation of HPCs in vivo.
Decreased quantity and quality of CD34 +
CD38 -early HPCs is dependent on pDCs during chronic HIV-1 infection
Increasing reports have demonstrated that chronic inflammation could lead to the functional exhaustion of BM HPCs [19, 22, 28] . Our recent study indicated that depletion of pDCs efficiently rescued human CD45 cell reconstitution in humanized mice with chronic HIV-1 infection [29] . Thus, we hypothesized that pDCs may be responsible for the depletion of CD34 + CD38
-early HPCs and their functional impairment during chronic HIV-1 infection.
To address the role of pDCs in the impairment of CD34 + CD38 -HPCs in HIV-1 infection, humanized mice with chronic HIV-1 infection were treated with a pDC-depleting antibody (15B) as in our previous report [29] . Similarly, the plasma viral load was increased upon the depletion of pDCs and maintained at a higher level until termination (S4A Fig) . Notably, the depletion of pDCs significantly changed the percentage of CD34 + CD38 -early HPCs in the BM from humanized mice with chronic HIV-1 infection (Fig 5A) . Pooled data further confirmed + HPCs (E) in BM of mock (n = 4) and HIV-1-infected (n = 6) humanized mice. Data are shown as the mean ± s.e.m. *P < 0.05 (two-tailed unpaired Student's t-test). 
CD34
+ cells from BM of humanized mice were isolated and submitted for gene expression analysis by cDNA array (Fig 6A) , as described in a previous study [29] . A total of 3114 genes were significantly up-regulated, and 2994 genes were down-regulated spontaneously in CD34 + HPCs from HIV-1-infected humanized mice as compared to mock-treated mice (fold change > 2, Fig 6B and S5 Fig) . Astonishingly, pDCs depletion during chronic HIV-1 infection in mice restored most of the interferon-stimulating genes (ISGs) to levels found in non-infected animals (S6A and S6B Fig) . Along with the recovery of ISG gene expression, only 924 genes were significantly up-regulated, and 364 genes were down-regulated in BM CD34 + HPCs with pDCs depletion as compared to mock-treated mice (fold change > 2, Fig 6B and S5 Fig) . Thus, pDCs depletion resulted in a restoration of a total of 5664 genes among 6108 genes (> 92.7%) that changed during HIV-1 infection in humanized mice, drawing back the whole gene expression profile to a pattern quite similar to that in mock-infected mice (Fig 6B and S5 Fig) .
We then searched the GeneGo database to identify potentially relevant pathways in the genes influenced by chronic HIV-1 infection. The hematopoietic cell lineage was the most affected pathway induced by chronic HIV-1 infection among the top 15 pathways, whereas those dysregulated genes were also significantly restored to mock levels in pDC-depleted BM CD34 + HPCs of humanized mice chronically infected with HIV-1 (Fig 6C) . We comprehensively analyzed the 88 genes in the hematopoietic cell lineage pathway (S7A Fig) and found that HIV-1 infection induced a significant up-regulation of 27 genes and down-regulation of 28 genes in humanized mice relative to mock controls (S7B Fig). However, depletion of pDCs during HIV-1 infection only induced a significant change in expression of one gene in relation to mock controls (S7B Fig) . Summarized data further indicated that although HIV-1 infection led to a significant change of most of the genes with more than a 2-fold change, pDC depletion could attenuate the up-regulation of genes and restored the down-regulated genes to normal levels during chronic HIV-1 infection (Fig 6D and S7C Fig) . In particular, some genes related to the HPC quiescent state (DTX3L and CXCR4) [30] , colony forming capacity (CD34, CD38, FLT3 and TGFBR1-3) [31] , self-renewal and expansion capacity (Notch1-2, Jagged1-2 and Hes-1) [32, 33] , as well as several important cell death genes were significantly altered by chronic HIV-1 infection, while pDCs depletion in HIV-1-infected humanized mice largely restored the abnormal expression of these genes to a similar pattern as seen in mock-infected mice ( Fig  6E and 6F , S1 Table) . Simultaneously, we also performed mRNA expression analysis using spleen-derived CD45 These data strongly suggest that pDCs has relatively unique effects on the numerical reduction and functional impairment of BM CD34 + HPCs in HIV-1 chronically infected humanized mice, contributing to the suppression of hematopoiesis characterized by dysregulation of gene expression profiles. We finally tested whether IFN-I directly up-regulates CD38 expression on HPCs in vitro. As shown in S9A and S9B Fig, neither IFN- with the observed pancytopenia in HIV-1 infected patients [13] . In this study, we found that CD34 [29, [37] [38] [39] . In addition, pDCs can secrete other pro-inflammatory cytokines, including TNF-α and IL-6. These chronic inflammatory cytokines can lead to exhaustion of hematopoiesis [19, 22, 28] . Most importantly, pDCs are the major IFN-I-producing cells during HIV-1 infection [29, 40, 41] . Currently, IFN-I is perhaps the primary contributor, since depletion of pDCs completely abolished IFN-I responses in humanized mice with chronic HIV-1 infection [29] . IFN-I has been recently demonstrated to be actively involved in immune pathogenesis of chronic virus infection [39, [42] [43] [44] [45] . Our data indicate that IFN-I did not directly affect CD38 expression on HPCs in vitro during shortterm culture although it possibly promote the maturation of embryonic hematopoietic stem cells [46] . Other factors associated with chronic HIV-1 infection may contribute to IFN-induced HPC depletion and will be investigated in future study. Of course, we could not exclude the possibility that HIV-1 products are involved in the dysregulation of hematopoietic development. For example, HIV-1 Nef has been found to be responsible for hematopoietic defects of the BM in HIV-1 infection, dependent on the presence and activation of the PPARγ signaling pathway [17] . Thus, pDCs may contribute to abnormal hematopoiesis during chronic HIV-1 infection directly through viral infection or indirectly via diverse cytokines. Taking these studies into consideration, we also propose that HIV-1 infection may affect HPC function through multiple mechanisms (S10 Fig). Future studies should investigate in detail the individual factors responsible for compromising hematopoietic activity.
In summary, pDCs play a pivotal role in the immune-pathogenesis and hematopoiesis depression induced by chronic HIV-1 infection. This study, therefore, provides new insight into HIV-1-induced dysregulation of hematopoiesis and provides a novel strategy for treating abnormal hematopoiesis during chronic HIV-1 infection.
Materials and methods
Ethics statement
Approval for animal work was obtained from the University of North Carolina Institutional Animal Care and Use Committee (IACUC ID: 14-100). The study protocol on human samples was approved by the Institutional Review Board and the Ethics Committee of Beijing 302 Hospital in China. The written informed consent was obtained from each subject. Human BM samples were obtained from adult donors with liver transplantation as healthy controls and from HIV-1-infected adult patients for pathological diagnosis. Human fetal livers and thymuses (gestational age 16 to 20 weeks) were obtained from medically indicated or elective termination of pregnancies through a non-profit intermediary working with outpatient clinics (Advanced Bioscience Resources, Alameda, CA). Written informed consent from the maternal donor was obtained in all cases under regulations governing the clinic. All animal studies were conducted following NIH guidelines for housing and care of laboratory animals. The project was reviewed by the University's Office of Human Research Ethics, which determined that this submission does not constitute human subjects research as defined under federal regulations [45 CFR 46. 102 (d or f) and 21 CFR 56.102(c)(e)(l)].
Construction of humanized mice
We constructed humanized Balb/c rag2-γc (DKO) mice and Nod-rag1-γc (NRG) mice (The Jackson Laboratory) in a similar manner as previously reported [36] . Briefly, human CD34 + cells were isolated from 16-to 20-week-old fetal liver tissues (Advanced Bioscience Resources, Alameda, CA). Tissues were digested with liver digest medium (Invitrogen, Frederick, MD). The suspension was filtered through a 70-μm cell strainer (BD Falcon, Lincoln Park, NJ) and centrifuged at 150 × g for 5 minutes to isolate mononuclear cells by Ficoll. After selection with the CD34 + magnetic-activated cell sorting (MACS) kit, CD34 + HPCs (0.5 × 10 6 ) were injected into the liver of each 2-to 6-day-old DKO or NRG mice, which had been previously irradiated at 300 rad. More than 95% of the humanized mice were stably reconstituted with human leukocytes in the blood (60-90% at 12-14 weeks). Each cohort had similar levels of engraftment. All mice were housed at the University of North Carolina at Chapel Hill.
HIV-1 virus stocks and infection of humanized mice
An R5-tropic strain of HIV-1, JR-CSF, was used for chronic HIV-1 infection. All viruses were generated by transfection of 293 T cells (SIGMA-ALORICH, Cat#12022001-1VL) with pYK-JRCSF (NIH AIDS reagents program, Cat# 2708). Humanized mice with stable human leukocyte reconstitution were infected with JR-CSF at a dose of 10 ng p24/mouse, through intravenous (i.v.) injection. Humanized mice infected with 293 T mock supernatant were used in control groups (S2 Fig) . Viral genomic RNA in plasma was extracted using the QIAamp Viral RNA Mini Kit (QIAGEN, Cat# 52904) according to the manufacturer's instruction. HIV-1 replication (genome copies/ml plasma) was measured by real-time PCR (ABI Applied Biosystem) or by p24-FACS detection of productively infected human T cells.
Depletion of human pDCs in humanized mice
A monoclonal antibody specific to blood dendritic cell antigen-2 (BDCA2), 15B, was used to treat humanized mice through intra-peritoneal (i.p.) injection (4 mg/kg) as previously reported [29] . Briefly, 15B was applied to mice at 7 weeks post-infection by injecting twice every week for another 4 weeks.
Animal termination and tissue processing
For chronic JR-CSF infection, mice were terminated at 12 week post-infection. On termination, total leukocytes were isolated from mouse lymphoid organs as previously described [29, [34] [35] [36] . Lymphoid tissues, including peripheral blood (PB), peripheral lymph nodes (pLN), mesenteric lymph nodes (mLN), spleen and BM were harvested for analysis. Red blood cells were lysed with ACK buffer, and the remaining cells were stained and fixed with 1% (wt/ vol) formaldehyde before FACS analysis. The total cell number was quantified by using Guava Easycytes with Guava Express software (Guava). Human BM cells were isolated by ficoll-hypaque density gradient centrifugation and collected for further analysis.
Antibodies and flow cytometry
Surface and intracellular fluorochrome-conjugated antibodies or reagents from Biolegend, BD Bioscience, eBioscience and R&D Systems were used in this study. For humanized mice, live human leukocytes (Y7 -mCD45 -hCD45 + ) were analyzed for HPC subsets or phenotypic expression by using the CyAn FACS instrument (Dako). Live/dead fixable violet dead cell dye (LD7) was purchased from Molecular Probes (Eugene, OR). For intracellular p24 staining, freshly isolated cells were collected for surface staining, followed by cell permeabilization using a Cytofix/Cytoperm kit (BD Bioscience) and intracellular staining and washing. The data were analyzed using Summit Software.
BrdU labeling in vivo
5-Bromo-2'-deoxyuridine (BrdU, Cat#: B5002, Sigma-Aldrich, St. Louis, MO) was first dissolved in water at a concentration of 10 mg/mL for stock in -20˚C. The BrdU stock was then diluted in 200 μL PBS and injected i.p. at 100 mg/kg body weight. Four hours later, the mice were terminated, and BM cells were collected. BrdU staining was performed according to the manufacturer's instructions. In brief, cells were first stained for surface markers and then incubated with a working solution of the BrdU staining buffer for 15 minutes, followed by incubation with DNase I (BIO-RAD, Cat#: 7326828) for 1 hour at 37˚C in the dark. Thereafter, the cells were stained with the FITC-conjugated anti-BrdU antibody for 30 minutes at room temperature in the dark and subsequently washed. The data were analyzed using Summit Software. In vitro HPC maturation and expansion experiments 
Colony-forming assays
Agilent microarray assay
RNA purification was carried out using the RNeasy Plus Mini Kit (Cat# 74134, QIAGEN, Venlo, Limburg, Netherlands) according to the manufacturer's instructions. DNase (QIA-GEN) treatment was added to the column to eliminate any potential DNA contamination during RNA preparations. Total RNA was checked for quantity, purity and integrity by capillary electrophoresis. RNA was amplified with Cy3-and Cy5-labeled CTP in separate reactions to produce differentially labeled samples and reference cDNAs. Total RNA (200 ng to 400 ng) was used as the starting material to prepare cDNA. Both samples were hybridized to the same microarray (UNC Genomic and Bioinformatics Core) using SurePrint G3 Human Gene Expression 8^60K Microarray Kit (Agilent). Agilent Feature Extraction v18 software was used to analyze all images. Gene expression values were quantified by the log2 ratio of the red channel intensity (mean) vs. green channel intensity (mean), followed by LOWESS normalization to remove the intensity-dependent dye bias.
Statistical analysis
Data were analyzed using GraphPad Prism software version 5.0 (GraphPad software, San Diego, CA). Data from different cohorts of mice were compared using a 2-tailed unpaired T test. All results were considered significant for P values < 0.05. 
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